US FDA asked to explain management of "disclosed conflicts" in trials
This article was originally published in SRA
US Senator Chuck Grassley (Republican – Iowa) has asked the Food and Drug Administration to explain how it handles reports of payments made by drug and device companies to doctors participating in clinical trials of their products to minimise potential bias1,2.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.